Emerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced a license agreement for its lead pipeline candidate Cantrixil (TRX-E-002-1). …
Kazia Therapeutics signs global agreement for lead candidate
March 4, 2021 BioPharmaLatest NewsAustralian Biotech
Latest Video
New Stories
-
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits
November 16, 2026 - -
First official US count confirms the broad uptake of GLP-1s for weight management
November 16, 2026 - - Latest News -
Can the PBS afford another agreement on the same terms?
November 16, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 13 November
November 13, 2026 - - Podcast -
A year on, Sanofi now asks staff to explain how they used AI
November 13, 2026 - - Latest News -
There is no need for AI to automate the care out of healthcare, Cohn warns
November 13, 2026 - -
Cochlear's global government affairs chief is putting AI to work
November 13, 2026 - - Latest News